Drugs / AMT-253
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05906862 | Nov 2023 → Sep 2026 overdue | neoplasm | Multitude Therapeutics | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06209580 | Jan 2024 → Apr 2026 overdue | cancer, melanoma | Multitude Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMT-253 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05906862 ↗ |
| Route | Intravenous | “Administered intravenously” NCT05906862 ↗ |